Trial Profile
A Phase Ib Study of Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Avelumab (Primary)
- Indications Meningioma
- Focus Pharmacodynamics; Proof of concept
- 13 Jun 2023 Status changed from active, no longer recruiting to discontinued.
- 04 Mar 2022 Status changed from recruiting to active, no longer recruiting.
- 07 Sep 2021 Planned End Date changed from 31 Aug 2024 to 30 Sep 2025.